Investor Overview

NYSE: RNN
$1.89 0.00 (0.000%)
Data as of 08/23/17 at 8:00 PM ET
Minimum 20 minute delay
High N/A
Low N/A
Volume N/A

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and SupinoxinTM (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.



©2017 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy